Prostate Cancer
Current Clinical Applications of PSMA-PET for Prostate Cancer Diagnosis, Staging, and Treatment.
January 9, 2025
Impact of intraprostatic PSMA maximum standardised uptake value following prostatectomy: a systematic review and meta-analysis.
January 8, 2025
Negative PSMA PET can be used to avoid unnecessary pelvic lymph node dissection in intermediate risk prostate cancer.
January 8, 2025
Clinical Feasibility of 3-D Acoustic Radiation Force Impulse (ARFI) Imaging for Targeted Prostate Biopsy Guidance.
January 8, 2025
Prostate MRI and clinicopathologic risk calculator to predict laterality of extraprostatic extension at radical prostatectomy.
January 8, 2025
Current Status of Sequential Treatment for Castration-resistant Prostate Cancer: A Retrospective Analysis.
January 7, 2025
Pelvic regional control with 25Gy in 5 fractions in SBRT for high risk prostate cancer: Pooled prospective outcomes from the SHARP consortium.
January 7, 2025
PIRADS 3 MRI lesions: are biopsies still necessary?
January 7, 2025
Selective treatment de-escalation in advanced prostate cancer: have we come full circle?
January 6, 2025
Incidence and Survival of Patients With Prostate Cancer in North-Rhine Westphalia, Germany.
January 6, 2025
Investigating the prognostic utility of GSTP1 promoter methylation in prostate cancer.
January 6, 2025
Alternate definitions of adverse pathology to predict a very high risk of metastasis in men with intermediate- and low-risk prostate cancer.
January 6, 2025